Skip to main content
Premium Trial:

Request an Annual Quote

BioSource Directors Reject Bio-Rad s $82M Acquisition Bid

NEW YORK, April 12 (GenomeWeb News) - BioSource International's directors unanimously rejected Bio-Rad Laboratories' $82 million offer to acquire the company, BioSource said yesterday.


In a letter to Bio-Rad CEO Norman Schwartz, the directors said they believed that Bio-Rad's April 6 offer of $8.50 per share was "significantly below BioSource's inherent value."


The directors further noted that prior to April 6, they had already been meeting with financial advisors to evaluate "strategic alternatives, including a possible sale of the company" to maximize financial results for its stockholders.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.